Quel est le prix pour Artiva Biotherapeutics, Inc. (ARTV)

Le prix pour Artiva Biotherapeutics, Inc. (ARTV) est $11.09

Quelle est la capitalisation boursière pour Artiva Biotherapeutics, Inc. (ARTV)

La capitalisation boursière pour Artiva Biotherapeutics, Inc. (ARTV) est $542.19M

Revenus de Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Année	Revenus	Changez
Pas assez de données pour les dates fournies.

Année

Revenus

Changez

Pas assez de données pour les dates fournies.

Entreprise	Revenus	Différence de revenus	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.74B	-	AU
Moderna, Inc. MRNA.US	$2.23B	-	US
Lonza Group AG LONN.SW	-	-	CH

Entreprise

Revenus

Différence de revenus

Pays